Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycol salicylate is a non-steroidal anti-inflammatory drug (NSAID) and a member of the salicylates, chemically known as 2-hydroxyethyl salicylate. It is formed by the condensation of the carboxy group of salicylic acid with one hydroxy group of ethylene glycol. Glycol salicylate is primarily used as an active ingredient in topical creams, sprays, and patches for the relief of mild to moderate muscle and joint pain, including aches, pains, stiffness, arthritis, sprains, or strains. Its mechanism involves inhibition of cyclooxygenase (COX) enzyme via its metabolite (salicylic acid), leading to decreased formation of pro-inflammatory prostaglandins[1][3][4][5]. The drug acts locally when applied topically and may also function as a counter-irritant by causing mild skin irritation that distracts from deeper musculoskeletal pain[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glycol salicylate.